Abstract

Human induced pluripotent stem cells (hiPSCs) could be used to generate autologous cells for therapeutic purposes, which are expected to be tolerated by the recipient. However, iPSC-derived grafts are at risk of giving rise to teratomas in the host, if residuals of tumorigenic cells are not rejected by the recipient. We have analyzed the susceptibility of hiPSC lines to allogeneic and autologous natural killer (NK) cells. IL-2-activated, in contrast to resting NK cells killed hiPSC lines efficiently (P=1.69x10-39). Notably, the specific lysis of the individual hiPSC lines by IL-2-activated NK cells was significantly different (P=1.72x10-6) and ranged between 46 % and 64 % in 51Cr-release assays when compared to K562 cells. The hiPSC lines were killed by both allogeneic and autologous NK cells although autologous NK cells were less efficient (P=8.63x10-6). Killing was partly dependent on the activating NK receptor DNAM-1 (P=8.22x10-7). The DNAM-1 ligands CD112 and CD155 as well as the NKG2D ligands MICA and MICB were expressed on the hiPSC lines. Low amounts of human leukocyte antigen (HLA) class I proteins, which serve as ligands for inhibitory and activating NK receptors were also detected. Thus, the susceptibility to NK cell killing appears to constitute a common feature of hiPSCs. Therefore, NK cells might reduce the risk of teratoma formation even after autologous transplantations of pluripotent stem cell-derived grafts that contain traces of pluripotent cells.

Highlights

  • Pluripotent stem cells hold great promises for regenerative medicine

  • RT-PCR analyses showed the activation of endogenous pluripotency genes (OCT4, NANOG, LIN28, and SOX2) in all three analyzed Human induced pluripotent stem cells (hiPSCs) lines compared to their parental keratinocytes (Fig 1B)

  • We have shown that both allogeneic and autologous IL-2-activated natural killer (NK) cells can kill hiPSCs and killing was mediated partly by DNAX accessory molecule (DNAM)-1

Read more

Summary

Introduction

Pluripotent stem cells hold great promises for regenerative medicine. They might become a source of cells and tissues for new cell replacement therapies, e.g. to treat heart failure or Parkinson’s disease. Autologous iPSCderived grafts would substantially reduce the risk of immune rejection, but they might on the other hand be at higher risk of teratoma formation than allogeneic transplants if residuals of pluripotent cells remain in the grafts after in vitro differentiation into the desired cell type or tissue [4]. This assumption is based on results showing that murine ESCs and iPSCs give rise to teratomas in immunocompetent syngeneic but usually not in immunocompetent allogeneic mice [4,5,6,7,8,9]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call